Search Result

Results for "

PLK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Polo-like Kinase (PLK) (121) AAK1 (1) Akt (3) Androgen Receptor (1) Antibiotic (2) Apoptosis (34) Aurora Kinase (4) Autophagy (8) Bacterial (1) Bcl-2 Family (3) Btk (2) c-Myc (3) CaMK (1) Caspase (2) CDK (6) DAPK (2) DNA/RNA Synthesis (2) Drug Isomer (1) E3 Ligase Ligand-Linker Conjugates (1) Ephrin Receptor (1) Epigenetic Reader Domain (10) ERK (2) Ferroptosis (1) FGFR (1) GSK-3 (1) HSP (2) IKK (1) IRAK (1) Itk (1) JAK (3) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (2) LRRK2 (2) MAP4K (1) MDM-2/p53 (3) MELK (1) Microtubule/Tubulin (4) Mitosis (4) MMP (1) Mps1 (3) mTOR (1) Na+/K+ ATPase (1) Necroptosis (1) NEKs (3) NF-κB (1) Organoid (2) p38 MAPK (2) PAK (1) PARP (1) PI3K (5) PI5P4K (1) PIN1 (1) PROTACs (5) RAR/RXR (3) Reactive Oxygen Species (ROS) (1) Reference Standards (4) Small Interfering RNA (siRNA) (15) STAT (2) TNK1 (3) Trk Receptor (2) ULK (1) VRK (1) Wee1 (1)
By Research Areas:	Cancer (120) Cardiovascular Disease (2) Endocrinology (1) Infection (1) Inflammation/Immunology (8) Metabolic Disease (2) Neurological Disease (8)
Click Chemistry:	Azide (1) Alkynes (2)
Oligonucleotides:	Rat Pre-designed siRNA Sets (5) Mouse Pre-designed siRNA Sets (5) Human Pre-designed siRNA Sets (5) siRNAs (15)

143

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Targets Recommended: Polo-like Kinase (PLK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10197

Wortmannin 160+ Cited Publications SL-2052; KY-12420	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic	Cancer
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and *Plk3* with IC₅₀s of 5.8 and 48 nM, respectively .

HY-12137

Volasertib 30+ Cited Publications BI 6727	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib induces mitotic arrest and apoptosis. Volasertib, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-15828

Onvansertib 5+ Cited Publications NMS-1286937; NMS-P937	Polo-like Kinase (PLK) Apoptosis	Cancer
NMS-1286937 is a potent, selective and orally available *PLK1* inhibitor, with an IC₅₀ of 2 nM.

HY-15160

TAK-960 2 Publications Verification	Polo-like Kinase (PLK)	Cancer
TAK-960 is an orally available, selective inhibitor of polo-like kinase 1 (PLK1), with an IC₅₀ of 0.8 nM. TAK-960 also shows inhibitory activities against PLK2 and PLK3, with IC₅₀s of 16.9 and 50.2 nM, respectively. TAK-960 inhibits proliferation of multiple cancer cell lines and exhibits significant efficacy against multiple tumor xenografts .

HY-50877

GSK461364 15+ Cited Publications GSK461364A	Polo-like Kinase (PLK)	Cancer
GSK461364 is a selective, reversible and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with a K_i value of 2.2 nM.

HY-18682

Centrinone 30+ Cited Publications LCR-263	Polo-like Kinase (PLK)	Cancer
Centrinone (LCR-263) is a selective and reversible inhibitor of polo-like kinase 4 (PLK4) with a K_i of 0.16 nM.

HY-15161

Ro3280 4 Publications Verification	Polo-like Kinase (PLK)	Cancer
Ro3280 is a potent, highly selective inhibitor of *PLK1* with an IC₅₀ and a K_d of 3 nM and 0.09 nM, respectively, and nearly has no effect on PLK2 and PLK3.

HY-11003

GW843682X 5+ Cited Publications GW843682	Polo-like Kinase (PLK)	Cancer
GW843682X is a selective, ATP-competitive inhibitor of *PLK1* and *PLK3, with IC₅₀*s of 2.2 nM and 9.1 nM, respectively, and is also >100-fold selective against ～30 other kinases.

HY-12300

Ocifisertib 4 Publications Verification CFI-400945 free base	Polo-like Kinase (PLK) Apoptosis	Cancer
CFI-400945 free base is a potent, selective and orally bioavailable *PLK4* inhibitor with a K_i and an IC₅₀ of 0.26 nM and 2.8 nM, respectively.

HY-12045

HMN-214 3 Publications Verification IVX-214	Polo-like Kinase (PLK)	Cancer
HMN-214, an orally bioavailable proagent of HMN-176, is an inhibitor of polo-like kinase-1 (plk1), with antitumor activity.

HY-15155

MLN0905 5 Publications Verification	Polo-like Kinase (PLK)	Cancer
MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC₅₀ value of 2 nM. MLN0905 can be used for the research of cancer .

HY-172737

RP-1664	Polo-like Kinase (PLK)	Cancer
RP-1664 is a selective and orally active *PLK4* inhibitor with an IC₅₀ of 3 nM. RP-1664 demonstrates exquisite selectivity over related kinases, including AURKA/B and PLK1. RP-1664 disrupts centriole biogenesis in cancer cells and leads an accumulation of *PLK4* and p21 protein. RP-1664 demonstrates increased sensitivity in TRIM37-high-expressing cells or tumors. RP-1664 exhibits anti-tumor activity in breast cancer and neuroblastoma research ^[1][2].

HY-18683

Centrinone-B 5+ Cited Publications LCR-323	Polo-like Kinase (PLK)	Cancer
Centrinone-B (LCR-323) is a potent and highly selective *PLK4* inhibitor, with a K_i of 0.59 nM.

HY-12134

Poloxin 3 Publications Verification	Polo-like Kinase (PLK)	Cancer
Poloxin is a non-ATP competitive Polo-like Kinase 1 (PLK1) inhibitor that targets the polo-box domain, with an IC₅₀ of appr 4.8 μM.

HY-108597

TC-S 7005 4 Publications Verification	Polo-like Kinase (PLK)	Cardiovascular Disease Inflammation/Immunology
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC₅₀s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively .

HY-13994

Mps1-IN-2	Mps1 Polo-like Kinase (PLK)	Cancer
Mps1-IN-2 is a potent, selective and ATP-competitive dual *Mps1/Plk1* inhibitor, with an IC₅₀ and a K_d of 145 nM and 12 nM for Mps1 and a K_d of 61 nM for Plk1.

HY-15158

SBE13 Hydrochloride	Polo-like Kinase (PLK) Autophagy Apoptosis	Cancer
SBE13 Hydrochloride is a potent and selective *Plk1* inhibitor, with an IC₅₀ of 200 pM; SBE13 Hydrochloride poorly inhibits Plk2 (IC₅₀>66 μM) or Plk3 (IC₅₀=875 nM).

HY-18009

(Z)-LFM-A13 3 Publications Verification	Btk Polo-like Kinase (PLK) JAK	Cancer
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM; LFM-A13 shows no effects on JAK1 and JAK3, Src family kinase HCK, EGFR and IRK.

HY-102069

3MB-PP1	Polo-like Kinase (PLK) CDK DAPK	Others
3MB-PP1, a bulky purine analog, is a Polo-like kinase 1 (Plk1) inhibitor. 3MB-PP1 blocks mitotic progression and cell division arise through target Plk1 in in cells expressing analog-sensitive Plk1 alleles. 3MB-PP1 specifically inhibits the activity of analog-sensitive Ssn3 (Cdk8). 3MB-PP1 inhibits Leu93 Mutant Zipper-interacting protein kinase (Leu93-ZIPK; IC₅₀=2 μM). 3MB-PP1 can be used for the research of hypha formation of Candida albicans and cell division .

HY-134775

PLK4-IN-1	Polo-like Kinase (PLK)	Cancer
PLK4-IN-1 (Example A6) is a *PLK4* inhibitor, with an IC₅₀ of ≤ 0.1 μM .

HY-12137A

Volasertib trihydrochloride 30+ Cited Publications BI 6727 trihydrochloride	Polo-like Kinase (PLK) Apoptosis	Cancer
Volasertib (BI 6727) trihydrochloride is an orally active, highly potent and ATP-competitive Polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 0.87 nM. Volasertib trihydrochloride inhibits PLK2 and PLK3 with IC₅₀s of 5 and 56 nM, respectively. Volasertib trihydrochloride induces mitotic arrest and apoptosis. Volasertib trihydrochloride, a dihydropteridinone derivative, shows marked antitumor activity in multiple cancer models .

HY-12300B

Ocifisertib fumarate 4 Publications Verification CFI-400945 fumarate	Polo-like Kinase (PLK)	Cancer
CFI-400945 fumarate is a potent, selective and orally bioavailable *PLK4* inhibitor with a K_i and an IC₅₀ of 0.26 nM and 2.8 nM, respectively.

HY-13647

HMN-176	Polo-like Kinase (PLK) Mitosis	Cancer
HMN-176 is a stilbene derivative which inhibits mitosis, interfering with polo-like kinase-1 (plk1), without significant effect on tubulin polymerization.

HY-128493

PLK4-IN-4	Polo-like Kinase (PLK)	Cancer
PLK4-IN-4 (compound 22) is a potent *PLK4* inhibitor with an IC₅₀ value of 7.9 nM. PLK4-IN-4 has the potential for the research of cancer .

HY-114302

CCB02 1 Publications Verification	Microtubule/Tubulin	Cancer
CCB02 is a selective CPAP-tubulin interaction inhibitor, binding to tubulin and competing for the CPAP binding site of β-tubulin, with an IC₅₀ of 689 nM, and shows potent anti-tumor activity. CCB02 shows no inhibition on the cell cycle- and centrosome-related kinases, or the phosphorylation status of Aurora A, Plk1, Plk2, CDK2, and CHK1 .

HY-110002

LFM-A13 1 Publications Verification	Polo-like Kinase (PLK) Btk JAK	Cancer
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

HY-132135

(1E)-CFI-400437 dihydrochloride	Polo-like Kinase (PLK)	Cancer
(1E)-CFI-400437 dihydrochloride is a potent *PLK4* (IC₅₀= 0.6 nM) inhibitor and selective against other members of the PLK family (>10 μM). (1E)-CFI-400437 dihydrochloride inhibits Aurora A, Aurora B, KDR and FLT-3 with IC₅₀s of 0.37, 0.21, 0.48, and 0.18 μM, respectively. Antiproliferative activity .

HY-149324

SP27	PROTACs Polo-like Kinase (PLK)	Cancer
SP27 is a PROTAC that can selective degrades *PLK4, with a DC₅₀* of 19.5 nM. SP27 can be used for the research of breast cancer .

HY-15159

Cyclapolin 9	Polo-like Kinase (PLK)	Cancer
Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC₅₀ of 500 nM. Cyclapolin 9 is inactive against other kinases .

HY-158031

PLK1/BRD4-IN-5	Apoptosis Polo-like Kinase (PLK) Epigenetic Reader Domain	Cancer
PLK1/BRD4-IN-5 (Compound SC10) is an orally active *PLK1* and BRD4 inhibitor with IC₅₀ values of 0.3  nM and 60.8  nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research .

HY-160558

PLK1/BRD4-IN-3	Epigenetic Reader Domain Polo-like Kinase (PLK)	Cancer
PLK1/BRD4-IN-3 (Compound 21) is a selective dual inhibitor for bromodomain 4 (BRD4) and polo-like kinase 1 (PLK1). PLK1/BRD4-IN-3 inhibits BRD4-BD1, PLK1 and BRDT-BD1, with IC₅₀s of 0.059, 0.127 and 0.245 μM, respectively .

HY-126249

AAPK-25	Aurora Kinase Polo-like Kinase (PLK) Apoptosis	Cancer
AAPK-25 is a potent and selective *Aurora/PLK* dual inhibitor with anti-tumor activity, which can cause mitotic delay and arrest cells in a prometaphase, reflecting by the biomarker histone H3 ^Ser10 phosphorylation and followed by a surge in apoptosis. AAPK-25 targets Aurora-A, -B, and -C with K_d values ranging from 23-289 nM, as well as PLK-1, -2, and -3 with K_d values ranging from 55-456 nM .

HY-148974

PLK1-IN-5	Polo-like Kinase (PLK)	Cancer
PLK1-IN-5 is a potent PLK1 inhibitor with an IC50 of < 500 nM. PLK1-IN-5 shows anticancer effects (WO2008113711A1; compound I-4) .

HY-173233

PLK1-IN-14	Polo-like Kinase (PLK)	Cancer
PLK1-IN-14 (Compound Hit-4) is a selective *PLK1* inhibitor. It has an IC₅₀ of 22.61 pM against *PLK1* and an IC₅₀ of 0.09 nM for inhibiting the proliferation of DU - 145 prostate cancer cells. PLK1-IN-14 can be used in the research of prostate cancer .

HY-169579

PLK1-IN-11	Polo-like Kinase (PLK)	Cancer
PLK1-IN-11 (Cluster 4, 16953209) is a *PLK1* inhibitor, with IC₅₀ of 1 μM. PLK1-IN-11 can be used in research on a variety of cancers, including pancreatic, ovarian, breast, and non-small cell lung carcinoma .

HY-N8692

Dihydrobaicalein	Polo-like Kinase (PLK) VRK	Cancer
Dihydrobaicalein is a *PLK1* Inhibitor with an IC₅₀ of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and *PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens* .

HY-149085

XS-060	RAR/RXR	Cancer
XS-060 is a potent anticancer agent and RXRα antagonist. XS-060 significantly induces RXRα-dependent mitotic arrest by inhibiting *pRXRα-PLK1 interaction. XS-060 inhibits p-RXRα interaction with PLK1 but has no effect on RXRα heterodimerization with RARγ. XS-060 inhibits the in situ interaction between p-RXRα and PLK*1 at the centrosome .

HY-146792

PLK1-IN-4	Polo-like Kinase (PLK)	Cancer
PLK1-IN-4 is a potent and selective *PLK1* inhibitor with IC₅₀ < 0.508 nM. PLK1-IN-4 has broad antiproliferative activity against a variety of cancer cell lines. PLK1-IN-4 induces mitotic arrest at the G2/M phase checkpoint, leading to cancer cell apoptosis. PLK1-IN-4 can be used for researching hepatocellular carcinoma .

HY-149100

PLK1-IN-6	Polo-like Kinase (PLK) Epigenetic Reader Domain	Cancer
PLK1-IN-6 is a potent and selective *PLK1* inhibitor, with an IC₅₀ of 0.45 nM. PLK1-IN-6 shows significant anti-proliferative activities against cancer cells .

HY-179149

PLK4-IN-6	Polo-like Kinase (PLK) Apoptosis	Cancer
PLK4-IN-6 (compound C05) is an *PLK4* inhibitor (IC₅₀ < 0.1 nM). PLK4-IN-6 has anti proliferative activity against various tumor cells, such as IMR-32 (IC₅₀ = 0.948 μM), MCF-7 (IC₅₀ = 0.979 μM), H460 (IC₅₀ = 1.679 μM) cells. PLK4-IN-6 can significantly induce cell apoptosis and block the cell cycle. PLK4-IN-6 can be used for research on various types of cancer .

HY-164955

*TTK/PLK1-IN-1*	Mps1 Polo-like Kinase (PLK)	Cancer
TTK/PLK1-IN-1 (Formula I) is the inhibitor for threonine tyrosine kinase (TTK) and polo-like kinase 1 (PLK1) with IC₅₀ of 7 nM and 72 nM. TTK/PLK1-IN-1 regulates spindle assembly checkpoint (SAC), and exhibits antitumor efficacy against TNBC .

HY-115589

YLT-11	Polo-like Kinase (PLK) Apoptosis	Cancer
YLT-11 is a potent, selective and orally active *PLK4* inhibitor with K_d values of >10000, 653, >10000, 5.2 nM for PLK1, PLK2, PLK3, PLK4, respectively. YLT-11 shows antiproliferative activity. YLT-11 induces Apoptosis and cell cycle arrest at G2/M phase. YLT-11 show anticancer activity .

HY-176734

CZL-S092	Polo-like Kinase (PLK)	Cancer
CZL-S092 is a *PLK4* inhibitor with an IC₅₀ value of 0.9 nM and excellent selectivity over other *PLK4* family members (PLK1, PLK2, and PLK3). CZL-S092 exhibits anti-neuroblastoma activity in vitro (IMR-32 cells, IC₅₀ = 1.143 μM). CZL-S092 inhibits cell migration and halts the cell cycle and induces apoptosis. CZL-S092 can be used in studies of various cancers including neuroblastoma cancer .

HY-172364

PLK1-IN-12	Polo-like Kinase (PLK)	Cancer
PLK1-IN-12 is a highly selective and orally active *PLK1* inhibitor with an IC₅₀ of 20 nM. PLK1-IN-12 shows more selective for PLK1 than PLK2 (IC₅₀: >10000 nM) and PLK3 (IC₅₀: 3953 nM). PLK1-IN-12 exhibits anticancer potency across a broad spectrum of cell lines. PLK1-IN-12 can be used in anti-leukemia research .

HY-134775A

PLK4-IN-3	Polo-like Kinase (PLK)	Cancer
PLK4-IN-3 is a less active absolute stereochemistry of PLK4-IN-1. PLK4-IN-1 is a *PLK4* inhibitor, with an IC₅₀ of 0.65 μM .

HY-173212

PLK1-IN-13	Polo-like Kinase (PLK) c-Myc Apoptosis	Cancer
PLK1-IN-13 is a selective and orally active *PLK1* inhibitor (IC₅₀: 0.27 nM). PLK1-IN-13 also inhibits PLK2 (IC₅₀: 12.72 nM) and PLK3 (IC₅₀: 4.12 nM). PLK1-IN-13 arrests cell at G2 phase, induces apoptosis and down-regulates the transcription of the proliferation-related oncogene c-MYC. PLK1-IN-13 inhibits tumor growth, and can be used for research of acute myeloid leukemia (AML) .

HY-161521

PLK1-IN-10	Polo-like Kinase (PLK)	Cancer
PLK1-IN-10 (Compound 4Bb) is an orally active *PLK1* PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death .

HY-172880

PLK1-IN-15	Polo-like Kinase (PLK) Apoptosis	Cancer
PLK1-IN-15 (Compound 7n) is a PLK1 inhibitor (IC₅₀: 38.5 nM). PLK1-IN-15 exhibits antiproliferative activity against HepG2, Huh7, H1299 and A549 cells (IC₅₀: 2.03, 2.08, 4.79 and 17.11 μM, respectively). PLK1-IN-15 induces cell cycle arrest at the G2/M phase and apoptosis, and has anticancer activity .

HY-160557

PLK1/BRD4-IN-2	Epigenetic Reader Domain	Cancer
PLK1/BRD4-IN-2 (compound 15) is a BI-2536 (HY-50698) analog and dual inhibitor that targets both Polo-like kinase 1 (PLK1) and BRD4bromodomain (BRD4-BD1 IC₅₀=28 nM, PLK1 IC₅₀=40 nM) .

HY-143471

WNY0824 PLK1/BRD4-IN-1	Polo-like Kinase (PLK) Epigenetic Reader Domain Apoptosis Androgen Receptor c-Myc	Cancer
WNY0824 (PLK1/BRD4-IN-1) is an orally active dual inhibitor of *PLK1* and BET protein families, with IC₅₀ values of 22, 402.5, 150.7, 103.9, and 311.9 nmol/L for *PLK1, BRD2, BRD3, BRD4, and BRDT, respectively. WNY0824 induces cell cycle arrest and apoptosis by inhibiting AR- and MYC*-mediated transcriptional processes. In addition, WNY0824 also inhibits tumor growth in Enzalutamide (HY-70002) resistant CRPC xenograft tumor models .

Cat. No.	Product Name	Type

HY-W286743

Nε-(Carboxymethyl)-L-lysine

1 Publications Verification

CML; N6-(Carboxymethyl)-L-lysine; Nε-(1-Carboxymethyl)-L-lysine

Biochemical Assay Reagents

Nε-(Carboxymethyl)-L-lysine (CML) is an orally active advanced glycation end product. Nε-(Carboxymethyl)-L-lysine upregulates the expression of PLK1 and CEP20, and induces the activation of RAGE and ERK/NFκB. Nε-(Carboxymethyl)-L-lysine drives centrosome amplification. Nε-(Carboxymethyl)-L-lysine induces malignant transformation of hepatocytes and promotes the development of hepatocellular carcinoma. Nε-(Carboxymethyl)-L-lysine induces epithelial-mesenchymal transition in osteosarcoma cells and enhances their migration and invasion properties .

HY-110002

LFM-A13 1 Publications Verification	Biochemical Assay Reagents
LFM-A13 is a potent BTK, JAK2, *PLK* inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC₅₀s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research

HY-50698G

BI 2536	Biochemical Assay Reagents
BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual *PLK1* and BRD4 inhibitor with IC₅₀s of 0.83 and 25 nM, respectively . BI-2536 suppresses IFNB (encoding IFN-β) gene transcription .

Cat. No.	Product Name	Target	Research Area

HY-180989

*PROTAC PLK1 Degrader-2*	PROTACs Polo-like Kinase (PLK) Apoptosis	Cancer
PROTAC PLK1 Degrader-2 (Compound NC1) is a PLK1 PROTAC degrader with an K_d of 6.06 μM. PROTAC PLK1 Degrader-2 significantly inhibits the proliferation of HeLa cells, induces cell cycle arrest and apoptosis. PROTAC PLK1 Degrader-2 exhibits significant anti-tumor activity in a HeLa cell xenograft tumor mouse model. PROTAC PLK1 Degrader-2 can be used for the study of cervical cancer.

HY-180991

Arg12-AHX	E3 Ligase Ligand-Linker Conjugates	Cancer
Arg12-AHX is a synthetic E3 ligase-ligand conjugate that can be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989). PROTAC PLK1 Degrader-2 is a PLK1 PROTAC degrader with anti-tumor activity .

HY-180990

POI ligand-3	Ligands for Target Protein for PROTAC Polo-like Kinase (PLK)	Cancer
POI ligand-3 (Compound 4j) is a type of peptide-based PLK1 PBD inhibitor. POI ligand-3 can act as a target protein ligand and be used for the synthesis of PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989) .

HY-P11631

Arg12	Ligands for E3 Ligase	Cancer
Arg12, a 12-amino acid peptide sequence, is an E3 ubiquitin ligase ligand. Arg12 can be used to synthesize PROTACs, such as PROTAC PLK1 Degrader-2 (HY-180989). Arg12 can also act as a cell transmembrane peptide (CPP), facilitating the entire molecule to enter the cell .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10197

Wortmannin 160+ Cited Publications SL-2052; KY-12420	Infection Structural Classification Human Gut Microbiota Metabolites Microorganisms Classification of Application Fields Antibiotics Endogenous metabolite Disease Research Fields Other Antibiotics Source Classification	Organoid PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC₅₀ of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and *Plk3* with IC₅₀s of 5.8 and 48 nM, respectively .

HY-112356

Scytonemin	Alkaloids Microorganisms Classification of Application Fields Sunscreen Cosmetic Research Indole Alkaloids Source Classification	Apoptosis Reactive Oxygen Species (ROS) Polo-like Kinase (PLK)
Scytonemin is a hydrophobic alkaloid pigment that can be isolated from the outer sheath of cyanobacteria. Scytonemin has protective function against short-wave solar ultraviolet (UV) radiation, which can reduce the generation of reactive oxygen species (ROS) and the formation of DNA damage. Scytonemin also has anti-inflammatory and anti-proliferative activities, produces concentration-dependent inhibition (IC₅₀=2.0 μM) of polo-like kinase 1 (PLK1)-mediated cdc25C phosphorylation, and plays an important role in regulating the G2/M transition in the cell cycle. It can be used in the research of cancer, acute inflammation and sunscreen cosmetics .

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	Structural Classification Animals Classification of Application Fields Other Diseases Disease Research Fields Steroids Source Classification	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail and *PLK1* pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models .

HY-N8692

Dihydrobaicalein	Structural Classification Flavonoids Labiatae Flavonones Plants Medicago truncatula Gaertn. Source Classification	Polo-like Kinase (PLK) VRK
Dihydrobaicalein is a *PLK1* Inhibitor with an IC₅₀ of 6.3 μM. Dihydrobaicalein also inhibits VRK2 and *PLK2. Dihydrobaicalein is a natural product that can be isolated from Scutellaria scandens* .

HY-10197R

Wortmannin (Standard) SL-2052 (Standard); KY-12420 (Standard)	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	Organoid Reference Standards PI3K Polo-like Kinase (PLK) Autophagy Antibiotic
Wortmannin (Standard) is the analytical standard of Wortmannin. This product is intended for research and analytical applications. Wortmannin (SL-2052; KY-12420) is a potent, selective and irreversible PI3K inhibitor with an IC50 of 3 nM. Wortmannin also blocks autophagy formation, and potently inhibits Polo-like kinase 1 (PlK1) and Plk3 with IC50s of 5.8 and 48 nM, respectively .

HY-N13795

3,4,3'-Tri-O-methylflavellagic acid	Terminalia paniculata Roth Structural Classification Combretaceae Phenols Polyphenols Plants Source Classification	Polo-like Kinase (PLK) Microtubule/Tubulin
3,4,3'-Tri-O-methylflavellagic acid is a flavonoid inhibitor that targets αβ-tubulin (colchicine binding site) and polo-like kinase-1 (PLK-1), and can be isolated from the roots of Anogeissus leiocarpus. 3,4,3'-Tri-O-methylflavellagic acid interferes with microtubule assembly dynamics and kinase activity, exhibiting anti-cancer cell proliferation and potent anti-nociceptive effects .

Recombinant Proteins Recommended:

Species:	Human (9) Mouse (1)
Tag:	His (7) Strep (1) Tag Free (3) MBP (1)
Source:	sf9 insect cells (1) Sf9 insect cells (3) E. coli (6)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P76550

	PLK1 Protein, Human (Active, sf9, His) 3 Publications Verification Serine/threonine-protein kinase PLK1; PLK-1; STPK13	Human	Sf9 insect cells
	PLK1 is a serine/threonine protein kinase that centrally coordinates key functions during the M phase of the cell cycle. It regulates centrosome maturation, spindle assembly, cohesin removal, inactivates APC/C inhibitors, and controls mitotic exit and cytokinesis. PLK1 Protein, Human (sf9, His) is the recombinant human-derived PLK1 protein, expressed by Sf9 insect cells , with N-10*His labeled tag.

HY-P73706

	PLK1 Protein, Mouse (Active, sf9, His) Serine/threonine-protein kinase PLK1; PLK-1; STPK13	Mouse	Sf9 insect cells
	PLK1 is a serine/threonine protein kinase that centrally coordinates key functions during the M phase of the cell cycle. It regulates centrosome maturation, spindle assembly, cohesin removal, inactivates APC/C inhibitors, and controls mitotic exit and cytokinesis. PLK1 Protein, Mouse (sf9, His) is the recombinant mouse-derived PLK1 protein, expressed by Sf9 insect cells, with N-His labeled tag.

HY-P705858

	PLK1 Protein, Human (233a.a) Serine/threonine-protein kinase PLK1; PLK-1; STPK13	Human	E. coli

HY-P705859

	PLK1 Protein, Human (Inactive, T210V, sf9, His) Serine/threonine-protein kinase PLK1; PLK-1; STPK13	Human	sf9 insect cells

HY-P705589

	PLK2 Protein, Human (His-Strep) Serine/threonine-protein kinase PLK2; Polo-like kinase 2 (PLK-2; hPLK2); SNK; Serum-inducible kinase	Human	E. coli

HY-P703290

	PLK4 Protein, Human SAK; STK18	Human	E. coli
	PLK4 Protein, Human is the recombinant human-derived PLK4, expressed by E. coli , with tag Free labeled tag. ,

HY-P705861

	PLK4 Protein, Human (His) SAK; STK18	Human	E. coli

HY-P705596

	PLK3 Protein, Human (Active, sf9, His) CNK; FNK; PRK	Human	Sf9 insect cells

HY-P702889

	PLK3 Polo Box Domain Protein, Human (MBP, His) CNK; FNK; PRK	Human	E. coli
	PLK3 Polo Box Domain Protein, Human (MBP, His) is the recombinant human-derived PLK3 Polo Box Domain, expressed by E. coli , with C-6*His, N-MBP labeled tag. ,

HY-P705860

	PLK2 Protein, Human (C83S, V87T, A119S, A216S, C259A, C291S, L335T, Active) Serine/threonine-protein kinase PLK2; Polo-like kinase 2 (PLK-2; hPLK2); SNK; Serum-inducible kinase	Human	E. coli

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (5) Rabbit (4)
Reactivity:	Human (7) Rat (6) Mouse (4) Monkey (2) human (2)
Application:	IHC-P (4) ICC/IF (5) IF-Tissue (1) IP (5) WB (9) FC (3) ELISA (5)
Isotype:	IgG (4) IgG1 (3) IgG2a (1)
Conjugation:	Non-conjugated (9)
Clonality:	Monoclonal (5) Recombinant (2)
Modification:	Phosphorylated (1) Unmodified (6)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P84387

	PLK1 Antibody (YA4084) PLK; STPK13	WB, IHC-P, FC, ELISA	Human, Mouse, Rat, Monkey
	PLK1 Antibody (YA4084) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PLK1.

HY-P84387A

	PLK1 Antibody (YA4084)(PBS only) PLK; STPK13	WB, IHC-P, FC, ELISA	Human, Mouse, Rat, Monkey
	PLK1 Antibody (YA4084) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to PLK1.

HY-P80972

	PLK1 Antibody (YA843) PLK1; PLK; Serine/threonine-protein kinase PLK1; Polo-like kinase 1; PLK-1; Serine/threonine-protein kinase 13; STPK13	WB, ICC/IF, IP	Human, Rat
	PLK1 Antibody (YA843) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PLK1.

HY-P80972A

	PLK1 Antibody (YA843)(PBS only) PLK1; PLK; Serine/threonine-protein kinase PLK1; Polo-like kinase 1; PLK-1; Serine/threonine-protein kinase 13; STPK13	WB, ICC/IF, IP	Human, Rat
	PLK1 Antibody (YA843) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PLK1.

HY-P86183

	PLK1 Antibody (YA5875) Serine/threonine-protein kinase PLK1; Polo-like kinase 1; PLK-1; Serine/threonine-protein kinase 13; STPK13;	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	PLK1 Antibody (YA5875) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to PLK1.

HY-P85720

	PLK1 Antibody (YA5412) Serine/threonine-protein kinase PLK1; Polo-like kinase 1; PLK-1; Serine/threonine-protein kinase 13; STPK13;	IHC-P, WB	Human, Mouse, Rat
	PLK1 Antibody (YA5412) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to PLK1.

HY-P89634

	Snk Antibody (YA8978) SNK, PLK2, Serine/threonine-protein kinase PLK2, Polo-like kinase 2, Serine/threonine-protein kinase SNK, Serum-inducible kinase, PLK-2, hPLK2, hSNK	WB, ICC/IF, IF-Tissue, IP, ELISA	human
	Snk Antibody (YA8978) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to Snk.

HY-P80474

	*Phospho-PLK1 (Thr210) Antibody (YA161)* 1 Publications Verification	WB, ICC/IF, FC	Human
	Phospho-PLK1 (Thr210) Antibody (YA161) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-PLK1 (Thr210).

HY-P89782

	*SAK/STK18/PLK4 Antibody (YA9126)*	WB, IP, ELISA	human
	SAK/STK18/PLK4 Antibody (YA9126) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to SAK/STK18/PLK4.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-116423

JH295		Alkynes
JH295 is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 inhibits cellular Nek2 via alkylation of Cys22. JH295 is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-159493

BI2536-PEG2-Halo		Azide
BI2536-PEG2-Halo is a bifunctional molecule containing a ligand for Halo tag and a Polo-like kinase 1 (PLK1) inhibitor BI-2536 (HY-50698). BI2536-PEG2-Halo inhibits the proliferation of 293T cells with Halo-p53R273H(FL)-mCherry tag (IC₅₀=23 nM), exhibits selective toxicity against p53 mutant cancer cells .

HY-116423A

JH295 hydrate		Alkynes
JH295 hydrate is a potent, irreversible and selective NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 770 nM. JH295 hydrate inhibits cellular Nek2 via alkylation of Cys22. JH295 hydrate is inactive against the mitotic kinases, Cdk1, Aurora B or Plk1, and does not perturb bipolar spindle assembly or the spindle assembly checkpoint . JH295 (hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Targets Recommended: Polo-like Kinase (PLK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50698G

BI 2536	Polo-like Kinase (PLK) Apoptosis Epigenetic Reader Domain	Cancer
BI 2536 (GMP) is BI 2536 (HY-50698) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. BI 2536 is a dual *PLK1* and BRD4 inhibitor with IC₅₀s of 0.83 and 25 nM, respectively . BI-2536 suppresses IFNB (encoding IFN-β) gene transcription .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

PLK

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

GMP Molecules

Natural
Products